1. Type of sales or supply contract | Other sales or supply contracts | |
- Name of contract concluded | Government advance purchase agreement for COVID-19 vaccine (GBP510) | |
2. Details of contract | Contract amount (KRW) | 200,000,000,000 |
Sales of the latest fiscal year (KRW) | 225,610,784,857 | |
Ratio to sales (%) | 88.65 | |
Classified as a large-sized corporation? | No | |
3. Counterparty to contract | Korea Disease Control and Prevention Agency | |
- Relationship to company | - | |
4. Regions of sales or supply (markets served) | Republic of Korea | |
5. Contract period | Start date | 2022-03-21 |
End date | - | |
6. Terms and conditions of contract | Supply of a COVID-19 vaccine (GBP510) developed and produced by SK Bioscience | |
7. Effective date of contract (receipt of orders) | 2022-03-21 | |
8. Withholding of disclosure | Reasons for withholding disclosure | - |
Withholding period | - | |
9. Other matters to be factored into investment decisions | ||
- The sales of the latest fiscal year above are based on individual financial statements as of the end of 2020. - The contract amount above may change by mutual agreement between the contracting parties, and the amount may change when the contract quantity is changed. - The contract above may be terminated if Korean licensing and authorization are not obtained by the end of December 2022 or within the period extended by a separate agreement between the contracting parties. - The end date of the contract period above is 24 months from the date of licensing and authorization, and can be extended by agreement between the contracting parties. | ||
※ Related disclosure | - |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
SK Bioscience Co. Ltd. published this content on 22 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2022 08:09:07 UTC.